103 results about "Conotoxin" patented technology

The invention relates to linear y-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

The present invention relates conotoxin peptides that are analogs of the α-contoxin peptide RgIA. These conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the treatment of breast cancer.

This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C- terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear / non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.

The invention belongs to the fields of biochemistry and molecular biology, relates to an alpha-conotoxin peptide, and a medical composition, a preparation method and a purpose thereof, also relates to a propeptide of the conotoxin peptide, a nucleic acid construct, an expression vector, a transformed cell and a fusion protein, and also relates to a method for blocking acetylcholine receptors and a pharmaceutical purpose of the conotoxin peptide. The alpha-conotoxin peptide can specifically block the acetylcholine receptors (nAChRs) (such as alpha3beta2 nAChR), has high analgesic activity and addiction withdrawal activity and has a good application prospect in the aspects of preparing analgesics, smoking cessation or drug treatment medicines and the like.

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The α-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.

The present invention provides one kind of conotoxin MVII A and Trx fusion protein and its expression and application. Trx-CTX MVII A fusion protein is first cloned and expressed in colibacillus and then chromatographicaly purified, reduced and oxidized to obtain active Trx-CTX MVII A fusion protein. The obtained fusion protein may be applied in preparing analgetic for late stage cancer and AIDS and that for post-operation pain, burns, etc. and may be also applied in preparing medicine for cerebral ischemia and cerebral demage owing to its nerve protecting function. The present invention can obtain fusion protein with great molecular weight and relatively long half time, and may be applied in medicine development directly or as intermediate to be enzyme incised to obtain active omiga-conotoxin MVII A for further medicine development.

The invention provides an anti-wrinkle eye cream, wherein natural marine conotoxin is rich in various amino acids, the combined action of the natural marine conotoxin and dipeptide diaminobutyroyl benzylamide diacetate can improve ocular microcirculation and alleviate dark eye circles, and inhibit contraction of ocular muscles, thereby achieving the effect of reducing wrinkles; by jointing using hydrolyzed wheat protein, hydrolyzed collagen and hydrolyzed soybean protein, and utilizing compounding of the collagen, a moisturizing protective film is formed on a skin surface, so as to enhance theadherence of matrix outside epithelial cells, maintain a compact state of epithelial lipid monolayer molecular film, increase the level of cellular protein, and promote the synthesis of the collagen,thereby synergistically enhancing the anti-wrinkle effect; and ceramide, tocopherol acetate and saccharomyces lysate promote the skin metabolism, prevent pigment deposition, improve skin elasticity,lock moisture in the skin, repair skin barriers, and moisten the skin.

The invention belongs to the fields of biochemistry and molecular biology, relates to a new conopeptide, and a medicinal composition, a preparation method and uses thereof, also relates to a nucleic acid construct, an expression vector of the nucleic acid construct, a converted cell of the expression vector and a fusion protein of the conopeptide, and further relates to a method for blocking out an acetylcholine receptor, and pharmaceutical uses of the conopeptide. The new conopeptide K41JM and analogs thereof can specifically block out the acetylcholine receptor (nAChRs) (such as alpha9alpha10nAChR), have can treat neuralgia, cancer chemotherapy, breast cancer, lung cancer, wound healing, encephalomyelitis, epilepsy and ischaemia, and have good application prospects in the preparation of pain easing medicines, anticancer medicines and neuroscience tool medicines.

The invention relates to the field of polypeptide drugs, in particular to a conotoxin polypeptide, a preparation method and an application thereof, and especially relates to the conotoxin polypeptide acting on muscle-type nicotinic acetylcholine receptors. The amino acid sequence of the conotoxin polypeptide is HPA. The experimental results indicates that the conotoxin polypeptide HPA can act on the muscle-type nicotinic acetylcholine receptors to effectively inhibit the acetylcholine receptors, and can serve as antagonists of the muscle-type nicotinic acetylcholine receptors. The conotoxin polypeptide HPA can be used for preparing anti-wrinkle cosmetics, is broadly used and has good economic and social effects.

This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or γ-carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not α-conotoxin Ep1 or α-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke.

Linear conotoxin sequence and its encoded polypeptide sequence S6.8, its production and use are disclosed. The process is carried out by constructing cDNA library and cloning O-super-family conotoxin. It can delay vertebrate cerebral neuron cell membrane sodium-ion channel inactivation and sodium-ion channel opening time. It can be used as probe for ion-channel type and sub-type discrimination or as pilot compound to make research of medicine.

The present invention provides the GST fusion expression and application of a kind of conotoxin MVII A gene. GST-CTX MVII A recombinant fusion protein is cloned and expressed in colibacillus, and through GST affinity chromatography purified GST-CTX MVII A fusion protein is obtained. The fusion protein the present invention obtains may be applied in preparing medicine for treating intractable painof cancer and AIDS patient in the late stage, preparing analgesic for treating post-operation acute pain, pain of burn, biliary colic, intractable neuralgia, etc., and preparing medicine with nerve protecting function for treating cerebral ischemia and cerebral damage. The obtained fusion protein has relatively great molecular weight and relatively long half life in body and may be enzyme incisedto obtain active omiga-conotoxin MVII A small peptide for direct medicine development.

This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or γ-carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not α-conotoxin Ep1 or α-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke.

The invention relates to a new South China Sea conus M-superfamily toxin gene Lt3.2 and a polypeptide sequence lt3b coded by the same, and the application of the polypeptide in preparing tool medicine for the neurobiological research and analgesic drugs. By constructing cDNA library, the new M-superfamily toxin gene is obtained by cloning the South China Sea conotoxin, the cDNA sequence of Lt3.2 is shown by Sq. (400) 1 in the sequences table. As for the polypeptide (conotoxin lt3b) coded by the gene, the amino acid sequence of the precursor peptide is shown in Sq. (400) 2 of the sequences table, and the amino sequence of the presumed mature peptide is shown in Sq. (400) 3 of the sequences table. The neurotoxin lt3b of the invention can increase the opening current of the sodium channel and has an effect of abirritation. The neurotoxin lt3b can also be used for preparing tool medicine for the neurobiological research and analgesic agent.

The present invention provides a conotoxin alphaD-GeXXA gene, and a polypeptide and applications thereof, wherein the conotoxin alphaD-GeXXA gene is derived from South China Sea Strategoconus generalis, and the encoded conotoxin alphaD-GeXXA mature peptide can spontaneously form a homodimer so as to non-competitively inhibit acetylcholine receptors, such that the peptide has good application prospects in preparation of drugs or reagents for inhibition of acetylcholine receptors.

The invention belongs to the field of biochemistry and molecular biology and relates to a new alpha-conotoxin peptide, as well as a pharmaceutical composition, a preparation method and a use thereof. The invention further relates a propeptide, a nucleic acid construct, an expression vector, transformed cells and a fusion protein of the conotoxin peptide. The invention further relates to a method for blocking an acetylcholine receptor and a pharmaceutical use of the conotoxin peptide. The alpha-conotoxin peptide provided by the invention can specifically block the acetylcholine receptor (nAChRs (nicotinic acetylcholine receptors)) (such as alpha 6 / alpha 3 beta 2 beta 3 nAChR), further has the activity in treating addiction, neuropathic pain, Parkinson's disease, dementia, schizophrenia, depression, cancers and the like and has great application prospects in preparation of medicaments for quitting smoking and drugs and relieving pain, the medicaments for treating related mental disorders and the cancers, neuroscience tool medicaments and the like.

The invention belongs to the fields of biochemistry and molecular biology, and relates to alpha-conotoxin TxIC, a medicinal composition thereof, a preparation method thereof and an application. The invention further relates to a propeptide of conotoxin, a nucleic acid construct thereof, an expression vector thereof and a transformed cell, and a fused protein thereof. The invention further relates to a method for blocking an acetylcholine receptor and a pharmaceutical use of the conotoxin. The alpha-conotoxin disclosed by the invention can be used for specifically blocking the acetylcholine receptor (nAChRs) (such as alpha3beta2nAChR), has high analgesic activity and addiction withdrawal activity, and has a good application prospect on the aspect of preparation of analgesics, smoking addiction withdrawal medicaments or drug addiction withdrawal medicaments and the like.

The invention discloses conotoxin and a biological preparation method and application thereof. The preparation method includes the steps of firstly, cloning conotoxin gene to an expression cassette of a baculovirus carrier to obtain a recombination transfer expression carrier; secondly, subjecting the recombination transfer expression carrier and baculovirus DNA (deoxyribonucleic acid) to co-transfection so as to obtain recombination baculovirus; and thirdly, infecting insect hosts or insect cells with the recombination baculovirus, culturing expression conotoxin of the infected insect hosts, and collecting and purifying the expression products. The invention further provides optimized conotoxin gene which is evidently improved in expression efficiency in insect hosts compared with original gene. Bioactive conotoxin is expressed efficiently and safely in individual insect bioreactor by the aid of baculovirus expression systems, safety is quite high, and expression products can be directly applied to analgesia drugs and the like. The biological preparation method is high in expression efficiency, complete in post-processing, fine in bioactivity, low in production cost, available for scale production and the like.

The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.

The invention discloses a conotoxin analog Glu-Con-G[1-13], which is shorter than a Con-G peptide chain and small in molecular weight, and is obtained by replacing Gla3, Gla4, Gla7, Gla10 and Gla14 of the Con-G by natural amino acid Glu. The invention improves the defect that a Gla residue is hard to obtain to some extent. The Glu-Con-G[1-13] keeps the original activity, namely has certain interference effect on psychological dependence and physical dependence on morphine, is more easily synthesized artificially, and has smaller molecular weight of 1,588; however, the molecular weights of the Con-G and Glu-Con-G are respectively 2,265.19 and 2,044.14.

The invention relates to a mutant polypeptide compound lt14a-7 of South China Sea conus littertus linnaeus toxin lt14a, the preparation technology and application of the polypeptide. The peptide is obtained by replacing seventh lysine with lactamine through mature conotoxin lt14a, so as to be called as lt14a-7 (A is used for replacing the seventh K); the amino acid sequence direction is MCPPLCAPSCTNC from N end to C end. The lt14a-7 is prepared by the chemosynthesis method, and the polypeptide has the activity of antagonism neuron type acetylcholine receptor, important value in the development of analgesics, and good effect in the treatment of chronic pain caused by some diseases and receptor study.

The invention discloses seven alpha type conotoxin peptides and applications thereof. The peptide I has an amino acid sequence shown as the sequence 7 in a sequence table, and the last amino acid residue is amidated; the peptide II has an amino acid sequence shown as the sequence 8 in the sequence table, and the last amino acid residue is amidated; the peptide III has an amino acid sequence shownas the sequence 9 in the sequence table, and the last amino acid residue is amidated; the peptide IV has an amino acid sequence shown as the sequence 10 in the sequence table, and the last amino acidresidue is amidated; the peptide V has an amino acid sequence shown as the sequence 11 in the sequence table, and the last amino acid residue is amidated; the peptide VI has an amino acid sequence shown as the sequence 12 in the sequence table, and the last amino acid residue is amidated; and the peptide VII has an amino acid sequence shown as the sequence 13 in the sequence table. Proved by determination of activity, the seven peptides shown as a general formula I have an analgesic effect, wherein alpha type conotoxin peptides T-1, T-2, T-3 and T-4 have remarkable analgesic activity, and thealpha type conotoxin peptides T5-T7 also have remarkable analgesic activity, and the application value on the aspect of analgesia is achieved.

The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The α-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as α3β2 nAChRs, α6 / α3β2β3 nAChR or α3β4 nAChR or α6 / α3β4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.

The invention belongs to the field of biochemistry, molecular biology and neurosciences, and relates to a novel alpha O-conotoxin GeXIVA mutant and a pharmaceutical composition and application thereof. Specifically, the invention relates to a separated polypeptide. The amino acid sequence of the polypeptide is obtained by removing one or more amino acids in a mother sequence or replacing one or more amino acids in the mother sequence with the same number of L-type amino acids or D-type amino acids, wherein the mother sequence is SEQ ID NO:1, SEQ ID NO:62 or SEQ ID NO:63; and the polypeptide has an activity of blocking alpha9alpha10nAChR. The polypeptide disclosed by the invention can specifically block the alpha9alpha10nAChR, and has a good application prospect in the aspects of preparinganalgesic drugs, drugs for treating related mental diseases and cancers, neuroscience tool drugs and the like.

The invention relates to the technical field of polypeptide product preparation, in particular to a preparation method for mu-conotoxin. The method disclosed by the invention adopts a solid phase andliquid phase combination method to synthesize a mu-conotoxin product. A solid phase synthesis method is adopted for coupling peptides to resin in sequence from a C terminal to an N terminal accordingto the main chain of the mu-conotoxin, then, the peptides are cut from the resin to obtain a linear peptide, a natural oxidation method is adopted to oxidize the linear peptide to obtain mu-conotoxincrude peptide cyclization liquid with three pairs of disulfide bonds, and the crude peptide cyclization liquid is purified to obtain a high-purity refined peptide. By use of the technology disclosed by the invention, the high levels of aspects, including a refined peptide quality and a total yield, can be simultaneously realized by simple technical steps. Compared with a biological extraction technology, the preparation method disclosed by the invention is simple in reaction operation, short in days for construction, low in cost and high in yields, can easily achieve industrialized requirements and has a wide market prospect.

The invention provides a kit and a method for detecting mu-conotoxin (CTX) by using a single-chain antibody of gene engineering. Reagents in the kit comprise sample extracting solution, a standard reagent, an enzyme-labeled antigen reagent, cleaning solution, a bovine serum albumin (BSA) reagent, a color development substrate and stop solution. The method comprises the following steps of: processing samples; balancing the reagents; washing; adding the samples; incubating; washing; developing; stopping; and calculating the content of the mu-CTX in the samples. By the kit and the method, the single-chain antibody of the gene engineering for resisting mu-CTX micromolecules can be effectively expressed in escherichia coli; and the kit can be produced on a large scale, has an extremely simple whole production process, saves time, labor and money, can be conveniently and fast used and has low cost.

The invention discloses a matrine-based ionic liquid conotoxin polypeptide solution as well as a preparation method and application thereof, and a matrine-based ionic liquid conotoxin polypeptide preparation and a preparation method and application thereof. The preparation method comprises the following steps of providing conotoxin polypeptide mother liquor; adding matrine and organic acid into water to obtain a matrine organic acid ionic salt solution; and mixing the matrine organic acid ionic salt solution with the conotoxin polypeptide mother liquor to obtain the matrine -based ionic liquid conotoxin polypeptide solution. The prepared matrine-based ionic liquid conotoxin polypeptide solution is good in stability and biocompatibility, has slow-release and permeation-promoting effects, can be delivered in a transdermal way, can avoid easy degradation of polypeptide drugs in a digestive system under acidic and enzymatic reaction conditions and a first-pass effect of the liver in clinical application, and can reduce the influence of a skin barrier effect during external application.

The invention belongs to the field of cosmetics, and particularly relates to a composition with functions of improving skin conditions, removing wrinkles and resisting aging as well as a preparation method and application of the composition. The composition comprises the following main components of 0.01 %-1 % of snake venom-like peptide, 0.01 %-1 % of bee venom peptide, 0.01 %-1 % of scorpion venom peptide, 0.01 %-1 % of conotoxin and 0.01 %-1 % of aurelia aurita extract; and the composition can also comprise 0.01 %-1.0 % of anti-free radical component. The preparation process of the composition is simple and feasible, and the finished product can be used as mask liquid and the like to be directly applied to the skin surface, and can also be used as a production material to be used for manufacturing other skin care products; and the composition simultaneously has the effects of instantly removing wrinkles and resisting aging for a long time, simplifies the care process of people who need to remove wrinkles and resist aging, also has the functions of moisturizing, increasing skin elasticity, brightening skin color and the like, and comprehensively improves the skin conditions.

The invention discloses a South China Sea conotoxin encoding sequence and an application thereof, and concretely relates to a new South China Sea Calamiconus quercinus O-superfamily toxin gene Cq1.1, a polypeptide sequence Cq1.1 encoded by the new South China Sea Calamiconus quercinus O-superfamily toxin gene Cq1.1, a preparation method of the polypeptide, and applications of the polypeptide in neurobiology research, ion channel researches and pain easing drug exploitation. The new O-superfamily toxin gene Cq1.1 is found from the venom ducts of South China Sea Calamiconus quercinus through constructing a cDNA library, and Cq1.1 is obtained by using a high flux sequencing method. Mouse hot plate experiments and zebra fish intramuscular injection experiments of the recombinant conotoxin Cq1.1 prepared in the invention find that the recombinant conotoxin Cq1.1 has central analgesia and nerve anesthesia effects, so the recombinant conotoxin Cq1.1 can be used in classification identification of ion channel type and subtype or research exploitation of tool drugs, and preparation of pain easing drugs as a probe.